Compare BridgeBio Pharma Inc (BBIO) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Intuitive Surgical, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Intuitive Surgical, Inc. trades at $399.29 (market cap $138.97B). The key difference: Intuitive Surgical, Inc. is far larger — about 8.4× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| BBIO | ISRG | |
|---|---|---|
Market Cap | $16.61B | $138.97B |
Sector | Health | Health |
52-Week High | $90.17 | $592.85 |
52-Week Low | $47.29 | $332.02 |
Enterprise Value | $18.16B | $133.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Intuitive Surgical (ISRG) trades at $378.81, up 1.36% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows bullish technical signals despite premium valuations (P/E 43.44, P/S 12.35), supported by robust revenue growth reaching $10.06B in 2025 and expanding profit margins of 28.45%. Recent news highlights da Vinci 5 adoption driving procedure growth beyond urology.
Outlook remains positive with 68% analyst buy ratings and $519.05 price target suggesting 37% upside. Key risks include competitive pressure from Medtronic/J&J robots and potential U.S. procedure softness. The combination of durable demand and innovation pipeline supports long-term growth potential for MedTech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
